This article has no abstract; the first 100 words appear below.

More than 7 years have passed since the regression of advanced lymphoma was first reported in a patient who had undergone the infusion of T cells engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen expressed on the surface of both normal and malignant B cells.1 Subsequent trials of CD19-targeted CAR T-cell therapy showed a complete response in some patients with relapsed or chemotherapy-refractory hematologic cancers for which there were no effective therapies.2-5 This personalized therapeutic approach entails the removal of peripheral-blood T cells from a patient, followed by in vitro activation, genetic modification, and expansion of . . .